IP Library Granted Patent US 8,263,638
Granted Patent B2
US 8,263,638 · App. 11/667,139 · Granted Sep 11, 2012

Dosing regimens for ion channel modulating compounds

Assignee: Cardiome Pharma Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,263,638
App. No.
11/667,139
Granted
Sep 11, 2012
Kind
B2
Abstract

Dosing regimens, routes of administration and methods for the treatment or prevention of arrhythmias are disclosed. In these methods, arrythmias (e.g. atrial fibrillation, atrial flutter, early after depolarizations and prolongation of QT interval) may be reduced or eliminated by administering ion channel modulating compounds to a subject in need thereof via the dosing regimens disclosed herein.

Claims (22)

1. A method of treating acute atrial fibrillation in a human, wherein the method comprises administering a therapeutically effective amount of an ion channel modulating compound in a pharmaceutically acceptable carrier to the human, wherein the ion channel modulating compound is a compound of formula (Ib):

or a pharmaceutically acceptable salt thereof,

wherein the compound of formula (Ib) is administered in accordance with a dosage regimen comprising the following sequential steps:

a) administering over a first period of time a first dosage amount of 3.0 mg/kg to about 5.0 mg/kg of the compound of formula (Ib) to the human;

b) determining after a second period of time if the acute atrial fibrillation has terminated in the human;

c) if the acute atrial fibrillation has not terminated in the human after the second period of time, administering over a third period of time a second dosage amount of about 0.5 mg/kg to 2.0 mg/kg of the compound of formula (Ib) to the human; and

d) optionally repeating step b) and c) until the acute atrial fibrillation has terminated,

and wherein the first, second and any subsequent dosage amounts are administered parenterally.

2. The method of claim 1 wherein the dosage amount of the compound of formula (Ib) in step a) is 3.0 mg; kg and the dosage amount of the compound of formula (Ib) in step c) is 2.0 mg/kg.

3. The method of claim 1 wherein the first period of time is between about 5 and about 15 minutes, the second period of time is between 0 and about 15 minutes, and the third period of time is between about 5 and about 15 minutes.

4. The method of claim 1 wherein the first period of time is about 10 minutes, the second period of time is 15 minutes and the third period of time is about 10 minutes.

5. The method of claim 1 wherein the first dosage amount and the second dosage amount are both administered intravenously.

6. The method of claim 1 wherein the first, second and any subsequent dosage amounts are all administered intravenously.

7. The method of claim 1 wherein the compound of formula (I) is the hydrochloride salt of the compound of formula (Ib).

8. The method of claim 7 wherein the hydrochloride salt of the compound of formula (Ib) is administered in accordance with a dosage regimen comprising the following sequential steps:

a) intravenously administering over a first period of time of about 10 minutes a first dosage amount of 3.0 mg/kg of the hydrochloride salt of the compound of formula (Ib) to the human;

b) determining after a second period of time of about 15 minutes if the acute atrial fibrillation has terminated; and

c) if the acute atrial fibrillation has not terminated in the human after the second period of time, administering over a third period of time of about 10 minutes a second dosage amount of 2.0 mg/kg of the hydrochloride salt of the compound of formula (Ib) to the human.

9. The method of claim 1 wherein the total dosage amount of the ion channel modulating compound administered to the human produces in the blood plasma of the human a maximum concentration of greater than about 0.1 μg/ml of the ion channel modulating compound.

10. The method of claim 9 wherein the maximum concentration is between about 0.3 μg/ml and about 20 μg/ml.

11. The method of claim 10 wherein the maximum concentration is less than about 12 μg/ml.

12. The method of claim 10 wherein the maximum concentration is about 4 μg/ml.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CARDIOME PHARMA CORP.
To: CORREVIO CANADA CORP.
Reel/Frame 046831/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2018
From: CORREVIO CANADA CORP.
To: CORREVIO INTERNATIONAL SÀRL
Reel/Frame 046831/0227 →
RELEASE OF SECURITY INTEREST Recorded Jun 20, 2016
From: MIDCAP FINANCIAL TRUST
To: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
Reel/Frame 038961/0202 →
SECURITY INTEREST Recorded Jul 24, 2014
From: CARDIOME PHARMA CORP.; CARDIOME, INC.; ARTESIAN THERAPEUTICS, INC.; MURK ACQUISITION SUB, INC.; CORREVIO LLC; CARDIOME INTERNATIONAL AG; CORREVIO INTERNATIONAL SARL; CORREVIO (UK) LTD.; CARDIOME UK LIMITED; CORREVIO (AUSTRALIA) PTY LTD.
To: MIDCAP FUNDING V, LLC
Reel/Frame 033407/0314 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2007
From: BEATCH, GREGORY N.; CLOHS, LILIAN
To: CARDIOME PHARMA CORP.
Reel/Frame 019949/0870 →
Continuity (6)
Provisional Application 60626328 · Nov 8, 2004
Provisional Application 60652185 · Feb 10, 2005
Provisional Application 60676463 · Apr 29, 2005
Provisional Application 60702873 · Jul 27, 2005
Provisional Application 60729387 · Oct 21, 2005
Related Publication 20080171785A1 · Jul 17, 2008